Beta-Cell

Research on cell and drug therapies for the treatment of diabetes

Beta-Cell is a spin-off from the Diabetes Research Center (DRC) at the Brussels Free University (VUB). Daniël Pipeleers MD, PhD and Christel Hendrieckx, PhD co-founded Beta-Cell in 1998.

Gerard Dijkstra, PhD, CEO
Sue Swift, PhD, COO

Francis Vanderhoydonck, Chairman
François Stoop
André Meers, PhD
Christel Hendrieckx, PhD
Daniël Pipeleers, MD, PhD

Daniël Pipeleers, MD, PhD

Kranenberg 6
1731 Zellik
Belgium
Phone: +32-2-477-43-54
Fax: +32-2-477-43-50

BETA-CELL has developed BetaISLET, a normal porcine primary endocrine cell suspension isolated from fetal donor tissue. It can be used for studies of drug metabolism, pharmacology, toxicology and basic research. BetaGRAFT is a fetal porcine endocrine graft for human cell transplantation derived from SPF pigs and produced under cGMP conditions.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.